Scholarly Index
Ali McBride
Bristol-Myers Squibb (United States); 3,834 total citations; 378 total publications; best world rank #57
Bristol-Myers Squibb (United States)
3,834Total citations
378Total publications
32H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Biosimilars and Bioanalytical Methods | Lifetime | 267 | US 96 | 95.56 |
| Economic and Financial Impacts of Cancer | Lifetime | 486 | US 312 | 95.21 |
| Neutropenia and Cancer Infections | Lifetime | 556 | US 247 | 95.50 |
| Chemotherapy-related skin toxicity | Lifetime | 513 | US 248 | 86.68 |
| Methemoglobinemia and Tumor Lysis Syndrome | Lifetime | 247 | US 102 | 85.44 |
| Neutropenia and Cancer Infections | 2021-2025 | 57 | US 23 | 95.28 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 99 | US 37 | 94.37 |
| Blood disorders and treatments | 2021-2025 | 121 | US 32 | 89.92 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 869 | US 354 | 91.77 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 504 | US 225 | 89.27 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 523 | US 325 | 87.80 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 948 | US 211 | 80.13 |